Rare Disease 1 —
Training activity: 5

Details

Perform full chromosome analysis for patients referred for infertility testing or recurrent miscarriage using International System for Human Cytogenomic Nomenclature (ISCN) to describe genomic structural variant changes and select appropriate reflex testing.

Type

Developmental training activity (DTA)

Evidence requirements

Evidence the activity has been undertaken by the trainee​.

Reflection on the activity at one or more time points after the event including learning from the activity and/or areas of the trainees practice for development.

An action plan to implement learning and/or to address skills or knowledge gaps identified.

Reflective practice guidance

The guidance below is provided to support reflection at different time points, providing you with questions to aid you to reflect for this training activity. They are provided for guidance and should not be considered as a mandatory checklist. Trainees should not be expected to provide answers to each of the guidance questions listed.

Before action

What are the intended outcomes of the training activity?

• How will you prepare to perform chromosomal analysis for these specific rare disease referrals, ensuring you can identify both numerical and structural changes?
• What resources will you use to ensure you can interpret genomic variants and use the correct ISCN terminology to describe any structural changes identified?
• What do you need to know before embarking on the activity? Consider reviewing the International System for Human Cytogenomic Nomenclature (ISCN) manual and local Standard Operating Procedures (SOPs) for G-banded chromosome analysis.
• How will you prepare to select appropriate reflex testing, such as molecular analysis for Cystic Fibrosis or FMR1, if the initial chromosomal findings or clinical history warrant further investigation?

What do you anticipate you will learn from the experience?

• What specific insights do you hope to gain regarding the clinical significance of balanced versus unbalanced structural rearrangements in the context of reproductive failure?
• Thinking about what you already know about cytogenetics, how do you expect this activity to improve your technical proficiency in ‘stepping up’ from basic analysis to complex structural variant description using ISCN?

What actions will you take in preparation for the experience?

• What preparatory discussions have you planned to clarify the expectations for selecting reflex tests (e.g., when to trigger a microarray or a targeted molecular test)?
• What possible challenges do you anticipate—such as identifying low-level mosaicism or navigating complex ISCN strings for multi-break rearrangements—and how have you planned to handle them?
• How do you feel about embarking on this activity? Given that these results directly impact a patient’s future reproductive options and recurrence risks, how are you preparing for the professional responsibility of ensuring high-quality, accurate analysis?

In action

What are you doing?

• How are you currently approaching the chromosomal analysis of these postnatal samples? Why are you using these specific laboratory techniques (e.g., G-banding) for patients referred for infertility or recurrent miscarriage?
• What real-time decisions are you making as you scan the slides or images? For instance, what visual cues are leading you to suspect a specific genomic structural variant?
• Which parts of the analysis—such as identifying common numerical abnormalities—feel intuitive, and which—such as applying the correct ISCN terminology to describe a complex rearrangement—require more conscious effort?

How are you progressing with the activity?

• How effective are your current analytical actions in identifying the underlying genomic cause for the patient’s referral?
• What challenges are you facing in the moment—such as poor-quality preparations or a complex structural change that is difficult to characterise—and what are you learning from the analysis as it unfolds?
• How does this activity connect to your existing knowledge of cytogenetics and the clinical mechanisms of infertility (e.g., the significance of balanced translocations or inversions)?
• How are you determining the most appropriate reflex testing (e.g., molecular analysis for CF or FMR1) based on the chromosomal findings you are observing in real-time?

How are you adapting to the situation?

• Are there alternative testing strategies or higher-resolution techniques (such as microarray) you should consider in response to the specific structural changes you are seeing?
• What immediate support or guidance might you need from a senior Clinical Scientist or the ISCN manual to resolve a complex nomenclature string?
• As you select reflex tests and interpret these variants, are you ensuring that you are working strictly within your professional scope of practice?
• How are you adapting your approach to ensure that your interpretation of the clinical significance of identified variants remains aligned with current best practice guidelines?

On action

What did you notice?

• Summarise the key points of the experience, specifically detailing the analytical steps you took to perform the full chromosome analysis on postnatal samples.
• What were the essential clinical or technical details—such as a specific referral for recurrent miscarriage or a history of primary infertility—that most significantly influenced your choice of analysis and subsequent reflex testing?
• In your analysis, what specific structural or numerical changes did you observe that required description using ISCN terminology?

What did you learn from the activity?

• What specific skills or knowledge did you develop regarding performing chromosomal analysis for rare disease investigations?
• How has this activity improved your ability to interpret genomic variants, determine their clinical significance, and apply the correct ISCN nomenclature?
• Were there any unexpected challenges or successes—such as characterising a subtle balanced translocation or a low-level sex chromosome mosaicism—and what did you learn from these?
• In what ways did your reflection-in-action (the real-time decisions you made while viewing the chromosomes) influence the accuracy or efficiency of the final interpretation?
• How does the experience of accurately diagnosing the cause of infertility or miscarriage relate to the professional requirements for your post-programme practice as a Clinical Scientist?

What will you take from the experience moving forward?

• What specific areas for continued development in cytogenomic analysis or nomenclature have you identified as a result of this activity?
• How can you apply the learning from this experience to your routine practice to ensure the delivery of a safe and high-quality service for patients with rare diseases?
• Identify the specific actions you will now take—such as reviewing the latest ISCN manual updates or attending a national variant meeting—to support the assimilation of what you have learned?
• What support or resources (e.g., senior clinical scientist mentorship, specialized cytogenetic databases, or best practice guidelines) do you need to further develop your expertise in this field?

Beyond action

Have you revisited the experiences?

• How has your perspective on performing chromosomal analysis for infertility and recurrent miscarriage evolved as you have encountered a wider variety of structural variants since this activity?
• Comparing this activity with your Observed Training Activities (OTAs)— what specific observable behaviours and technical proficiencies have you assimilated into your routine practice?
• As part of a review of the module, what recurring themes have you identified regarding the clinical significance of balanced rearrangements or sex chromosome aneuploidy?
• Through discussion with senior colleagues, how has your understanding of the nuances of ISCN nomenclature for complex structural changes transformed as a result of mutual exchange?

How have these experiences impacted upon your current practice?

• Recognising that these individual analyses are not isolated incidents, how has this experience supported your development in wider professional areas, such as writing interpretative reports or presenting findings at multidisciplinary team (MDT) meetings?
• How have you applied the specialist knowledge of genomic structural variants gained from this activity since the original experience to improve the accuracy of your wider diagnostic practice?
• How is the learning from these cytogenetic investigations supporting your preparation for ‘in-person’ assessments for this module, such as Case-based Discussions (CBDs) on infertility or Direct Observations of Practical Skills (DOPS) related to variant classification?

How might these experiences contribute towards your future practice?

• What transferable skills—such as high-level analytical precision or the ability to synthesise complex technical data with clinical history—are you continuing to develop as you move toward becoming a Clinical Scientist?
• What clear actions have you identified for the continued development of your skills in cytogenomics to ensure you consistently deliver a safe and high-quality service in your future post-programme practice?

Relevant learning outcomes

#	Outcome
# 2	Outcome Perform targeted and chromosomal analysis for patients referred for investigation of rare disease.
# 3	Outcome Interpret genomic variants to investigate the clinical significance using appropriate nomenclature.
#	Outcome